Skip to main content
NeopharmCO.,LTD. logo

NeopharmCO.,LTD. — Investor Relations & Filings

Ticker · 092730 ISIN · KR7092730001 KO Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2026-03-03 Proxy Solicitation & In…
Country KR South Korea
Listing KO 092730

About NeopharmCO.,LTD.

https://neopharm.co.kr

Neopharm is a science-based company specializing in the development, manufacturing, and sale of dermatological skincare and cosmetic products. A pioneer in skin barrier research, the company focuses on restoring skin homeostasis. Its core innovation is the proprietary Multi-Lamellar Emulsion (MLE) technology, which mimics the natural lipid structure of the skin to repair and strengthen its protective functions. The company's primary product lines, including the flagship brand Atopalm, are specifically formulated for sensitive, dry, and compromised skin. These non-steroid solutions are grounded in dermatological science to address various skin concerns.

Recent filings

Filing Released Lang Actions
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Neopharm. It details the date, location, agenda items (such as financial statement approval, articles of incorporation changes, and director appointments), and voting procedures. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of upcoming meeting details and agenda items, which falls under the Proxy Solicitation & Information Statement category.
2026-03-03 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 95% confidence The document is a short regulatory announcement (816 characters) from NeoPharm regarding the scheduling of an Investor Relations (IR) meeting. It provides the date, time, location, and purpose of the meeting, and mentions that IR materials will be posted on the KRX website. Since it is an announcement of an event rather than the presentation itself, and it serves as a regulatory notification of corporate activity, it fits the 'Report Publication Announcement' or 'Regulatory Filings' category. Given the specific nature of announcing an IR event, 'RPA' is the most accurate classification.
2026-03-03 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as the 5% rule filing). It details the acquisition of shares by FIL Limited and its special related parties in the company 'Neopharm'. This type of document is specifically categorized as a Major Shareholding Notification (MRQ) in the provided schema.
2026-02-02 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from NeoPharm regarding the decision to pay a cash dividend. It specifies the dividend amount per share, the total dividend amount, the record date, and the approval process. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2026-01-27 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for Neopharm, detailing quarterly financial performance (revenue, operating profit, net income) for the period ending 2025-12-31. It provides key financial highlights and explicitly states that these are preliminary figures (잠정치) not yet audited. This fits the definition of an Earnings Release (ER). Q4 2025
2026-01-27 Korean
기업설명회(IR)개최
Investor Presentation Classification · 95% confidence The document is titled '기업설명회(IR) 개최' which translates to 'Investor Relations Presentation (IR) held'. It details the schedule, location, participants, purpose, and content of an investor presentation event, specifically mentioning the discussion of 2025 Q3 management results and Q&A. The document is short (813 characters) and focuses on announcing the event and its details rather than providing comprehensive financial data or analysis. Therefore, it fits the category of an Investor Presentation (IP) rather than an Interim Report (IR) or Earnings Release (ER).
2025-11-11 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.